Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible? [4]

Lung Cancer

Volumn 43, Issue 3, 2004, Pages 369-370

  Sumpter, Kate ^a   Harper Wynne, Catherine ^a   Yeoh, Cheng ^a   Popat, Sanjay ^a   Ashley, Sue ^a   Norton, Alison ^a   O'Brien, Mary ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; IFOSFAMIDE; NAVELBINE;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG RESPONSE; DYSPNEA; HEMATOLOGIC DISEASE; HEMOPTYSIS; HUMAN; INFECTION; LETTER; LUNG NON SMALL CELL CANCER; MALAISE; NEUTROPENIA; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

EID: 1242283945     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.09.019     Document Type: Letter

References (6)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual [patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
2. National Insitiute of Clinical Excellence. Guidance on the use of docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer. June 2001.
3. Fassella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F.et al. Randomised phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J. Clin. Oncol. 18:2000;2354-2362.
4. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M. et al. Prospective randomised trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2000;2095-2103.
5. Personal communication from Aventis.
6. Smith I.E., O'Brien M.E., Talbot D.C., Nicolson M.C., Mansi J.L., Hickish T.F.et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomised trial of three versus six courses of mitomycin. J. Clin. Oncol. 19:2001;1336-1343.